Get the Stockscreener App
0.3467
0.14%
-0.0005
Transcode Therapeutics Inc stock is traded at $0.3467, with a volume of 1.06M.
It is down -0.14% in the last 24 hours and down -15.44% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$0.3472
Open:
$0.3472
24h Volume:
1.06M
Relative Volume:
0.13
Market Cap:
$8.29M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0013
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-2.39%
1M Performance:
-15.44%
6M Performance:
-97.00%
1Y Performance:
-98.56%
1-Day Range:
$0.3342
$0.3595
1-Week Range:
$0.2742
$0.37
52-Week Range:
$0.2196
$65.67
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
0.3467 | 8.29M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus
TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
(RNAZ) Investment Report - news.stocktradersdaily.com
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan
TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PR Newswire
Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus
Offerings News Live Feed - Stock Titan
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com South Africa
Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com
TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus
TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN
TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus
TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com
TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN
For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com
Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com
CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com
Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com
Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com
Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com
why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance
TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail
TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus
TransCode's Cancer Drug Achieves Major Safety Milestone: 13 Patients Show No Toxicity in Latest Trial Data - Stock Titan
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug - Yahoo Finance
Selling Your TransCode Therapeutics Inc (NASDAQ: RNAZ) Stock? Here’s What You Need To Know - Stocksregister
TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus
TransCode Therapeutics Inc (RNAZ) can make a big difference with a little luck - Sete News
Does Arbe Robotics Ltd (ARBE) offer a good opportunity for investors? - Sete News
A Look at Murphy Oil Corp (MUR) Shares in the Recent Past Indicates Growth - Sete News
TransCode Therapeutics Inc (RNAZ) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
TransCode Therapeutics stock slides after announces to raise $10M securities offering - MSN
TransCode Therapeutics Inc (RNAZ) deserves closer scrutiny - uspostnews.com
Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreases By 59.2% - Defense World
(RNAZ) Trading Signals - news.stocktradersdaily.com
What’s The Deal With TransCode Therapeutics Inc (NASDAQ: RNAZ)? - Stocksregister
TransCode Therapeutics Faces Crucial Reverse Split Decision as Special Meeting Falls Short of Quorum - Stock Titan
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):